James Healy is Director of Y-mAbs Therapeutics, Inc.. Currently has a direct ownership of 31,603 shares of YMAB, which is worth approximately $261,672. The most recent transaction as insider was on Jun 11, 2024, when has been sold 3,495 shares (Common Stock) at a price of $0.0 per share, resulting in proceeds of $0. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 31.6K
0% 3M change
12.43% 12M change
Total Value Held $261,672

JAMES HEALY Transaction History

Date Transaction Value Shares Traded Shares Held Form
Jun 11 2024
BUY
Grant, award, or other acquisition
-
3,495 Added 9.96%
31,603 Common Stock
Jun 08 2023
BUY
Grant, award, or other acquisition
-
2,330 Added 7.65%
28,108 Common Stock

Also insider at

HGEN
HUMANIGEN, INC Healthcare
CHRS
Coherus BioSciences, Inc. Healthcare
BOLT
Bolt Biotherapeutics, Inc. Healthcare
NTRA
Natera, Inc. Healthcare
KRTX
Karuna Therapeutics, Inc. Healthcare
CINC
CinCor Pharma, Inc. Healthcare
AVBP
ArriVent Biopharma, Inc.
RAPP
Rapport Therapeutics, Inc.
BIOA
BioAge Labs, Inc.
JH

James Healy

Director
Menlo Park, CA

Track Institutional and Insider Activities on YMAB

Follow Y-mAbs Therapeutics, Inc. and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells YMAB shares.

Notify only if

Insider Trading

Get notified when an Y M Abs Therapeutics, Inc. insider buys or sells YMAB shares.

Notify only if

News

Receive news related to Y-mAbs Therapeutics, Inc.

Track Activities on YMAB